Thursday 26 September is the inaugural Childhood Brain Cancer Awareness Day. This year, we shine a light on Diffuse Intrinsic Pontine Glioma (DIPG), the most devastating of all childhood cancers.
We’ve just launched our Strategic Plan for 2018–2022. The culmination of months of consultation and thought, it provides a road map for achieving our vision as quickly as possible.
If doctors can reliably tell which children are most likely to get their leukaemia back, they can offer more intensive treatment options to prevent it.
Clinical trials are an essential step in translational research - taking a promising new anti-cancer treatment from bench to bedside.
In this third post in our series for Childhood Cancer Awareness month, you’ll see how experimental treatments emerge from the lab and get into use in the clinic.
Today marked the opening of the national clinical trial for Zero Childhood Cancer, with about 400 children with high-risk cancers expected to participate over the next 3 years.
We're starving neuroblastoma of polyamines with drug DFMO. But there won't be just one cure for such a diverse disease.
Venetoclax has been approved by the Australian Therapeutics Goods Administration (TGA) to treat an adult leukaemia. Could it one day treat childhood leukaemia?
Why is targeted treatment so vital for childhood cancer and what are the barriers to getting there? An article from The Conversation by two of our researcher-clinicians.
Find out more about the childhood cancer neuroblastoma, see what’s new in research into this disease and meet a neuroblastoma researcher